The challenge remains in an individualized approach, however, that oncogenic missense p53 mutants crosstalk within the cancer pathogenesis pathways and thus, even an personalized approach targeting just one individual pathway may not be highly effective (Mantovani et al., 2019). The gene discussed is TP53; the disease is cancer.